VSTM Verastem Inc.

3.41
+0.03  (+1%)
Previous Close 3.38
Open 3.37
Price To Book 2.03
Market Cap 251879773
Shares 73,865,036
Volume 3,031,118
Short Ratio
Av. Daily Volume 2,879,992

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 presentation ASCO June 2018.
Duvelisib
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
FDA Approval announced September 24, 2018.
Duvelisib - DUO
Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
VS-6063
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Edited Transcript of VSTM earnings conference call or presentation 12-Mar-19 8:30pm GMT
  2. 3 Penny Stocks That Could Make You Rich -- or Regretful
  3. Why Verastem Stock Broke Down Today
  4. Verastem (VSTM) Q4 2018 Earnings Conference Call Transcript
  5. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  6. Verastem (VSTM) Reports Q4 Loss, Misses Revenue Estimates
  7. Verastem: 4Q Earnings Snapshot
  8. Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
  9. Verastem Oncology to Present at Upcoming Investor Conferences
  10. Do Options Traders Know Something About Verastem (VSTM) Stock We Don't?
  11. Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies
  12. Why Verastem, Inc. (NASDAQ:VSTM) Could Have A Place In Your Portfolio
  13. Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy
  14. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  15. Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019
  16. Investor Expectations to Drive Momentum within Verastem, Molson Coors Brewing, SL Green Realty, UnitedHealth Group, TechTarget, and Icahn Enterprises — Discovering Underlying Factors of Influence
  17. Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  18. CORRECTING and REPLACING Verastem Oncology Announces Key Management Appointments
  19. Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology